(S)-6-(4-(butylthio)phenyl)-4-(4-methyl-3-(1H-tetrazol-5-yl)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one

ID: ALA4851952

Chembl Id: CHEMBL4851952

PubChem CID: 164611710

Max Phase: Preclinical

Molecular Formula: C24H24F3N5OS

Molecular Weight: 487.55

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCCSc1ccc([C@]2(C(F)(F)F)CC(c3ccc(C)cc3)=C(c3nnn[nH]3)C(=O)N2)cc1

Standard InChI:  InChI=1S/C24H24F3N5OS/c1-3-4-13-34-18-11-9-17(10-12-18)23(24(25,26)27)14-19(16-7-5-15(2)6-8-16)20(22(33)28-23)21-29-31-32-30-21/h5-12H,3-4,13-14H2,1-2H3,(H,28,33)(H,29,30,31,32)/t23-/m0/s1

Standard InChI Key:  HWZWJXDOSMQTGI-QHCPKHFHSA-N

Alternative Forms

  1. Parent:

    ALA4851952

    ---

Associated Targets(Human)

MGAT2 Tchem Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (703 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mgat2 Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (71 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 487.55Molecular Weight (Monoisotopic): 487.1654AlogP: 5.29#Rotatable Bonds: 7
Polar Surface Area: 83.56Molecular Species: ACIDHBA: 5HBD: 2
#RO5 Violations: 1HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 3.41CX Basic pKa: CX LogP: 5.70CX LogD: 4.09
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.35Np Likeness Score: -0.93

References

1. Turdi H, Chao H, Hangeland JJ, Ahmad S, Meng W, Brigance R, Zhao G, Wang W, Moore F, Ye XY, Mathur A, Hou X, Kempson J, Wu DR, Li YX, Azzara AV, Ma Z, Chu CH, Chen L, Cullen MJ, Rooney S, Harvey S, Kopcho L, Panemangelor R, Abell L, O'Malley K, Keim WJ, Dierks E, Chang S, Foster K, Apedo A, Harden D, Dabros M, Gao Q, Pelleymounter MA, Whaley JM, Robl JA, Cheng D, Lawrence RM, Devasthale P..  (2021)  Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders.,  64  (19.0): [PMID:34613725] [10.1021/acs.jmedchem.1c01356]

Source